



NECTAR LIFESCIENCES LIMITED

Sco 38-39, Sector 9 D, Madhya Marg, Chandigarh 160009, U.T., India

For immediate release

NecLife announces the receipt of South Africa 'MCC' approval for Ceftriaxone

Chandigarh, April 26, 2011

Nectar Lifesciences Limited (NecLife), a leading integrated pharmaceutical organization in India, today announced that it has received approval from South Africa, Medicines Control Council MCC for key product i.e. Ceftriaxone.

Business Opportunities in Japan

The South African approval marks a significant achievement and demonstrates further progress made by the Company in the highly regulated & stringent markets like South Africa. South Africa with a GDP of USD 527.5 billion (2010) is well poised to register steady growth in the pharma market in recent future on account of its expanding generic market. Currently, the market size of Pharma segment in South Africa is USD 3.5 billion and is expected to increase to USD 5 billion in next couple of years on account of the growth rates in the region & increasing incentives by governments for promoting generics like providing incentives for prescribing generics & increasing patient awareness. NecLife expects business potential for the approved molecule "Ceftriaxone" to be about USD 10 million.

Commenting on this development, Mr. Dinesh Dua, CEO & Director of Nectar Lifesciences Limited said:

"Receiving MCC approval for Ceftriaxone is yet another milestone & achievement for Nectar. MCC is one of the most stringent regulatory bodies globally & the fact that we have been approved by South African MCC is a key milestone which will complement the recent approvals by the Japanese, Korean & European authorities. This approval enables us to further augment our position in the cephalosporin market in major sterile molecules Ceftriaxone Sodium & Cefotaxime Sodium along with key oral molecules Cefuroxime Axetil, Cefixime Trihydrate & Cefpodoxime Proxetil."

"We remain excited about the current scenario of the pharma markets around the globe and are making stable progress towards securing approvals in other key markets"

For NECTAR LIFESCIENCES LTD.

**SUNDER LAL
• COMPANY SECRETARY**

About Nectar Lifesciences Limited (NecLife)

Established in 1995, NecLife (BSE code: 532649, NSE Id: NECLIFE, ISIN Id: INE023H01027) is a leading integrated pharmaceutical organization in India, offering a specialized comprehensive range of oral and sterile cephalosporin and Carbapenem active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The Company is growing presence in empty hard gelatine capsules (EHGCs) and menthol products. NecLife is one of the largest manufacturers of cephalosporin range of products and has an established brand presence in 20 states across India and 50 countries across five continents. NecLife has a global leadership position in 3 oral molecules and global No. 2 position in 2 sterile molecule. The Company has 11 manufacturing facilities - eight in Derabassi, Punjab (API and menthol units), two in Baddi, Himachal Pradesh (FDF and EHGC plants) and one in Jammu (menthol plant). NecLife's products include Oral and sterile cephalosporin, Carbapenem and other APIs, FDFs, Empty hard gelatin capsules and Menthol and allied products.

Additional information on NecLife is available on the Company website www.neclife.com.

Investor contacts

Dinesh Dua

Nectar Lifesciences Limited

Phone: +91 172 304 7766

Fax: +91 172 503 3537

Email: dinesh.dua@neclife.com

Ishan Selarka


Citigate Dewe Rogerson

Phone : +91 22 6645 1232

Fax: +91 22 6645 1213

Email: ishan@cdr-india.com

Note: This document contains 'forward-looking' statements at places. The Company has operations across several segments of business and remains subject to undetermined contingencies and risks. Nectar Lifesciences would not be liable for any action undertaken based on such 'forward-looking' statements and does not commit to revising/updating them publicly.

For Nectar Lifesciences Limited

Company Secretary